ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, dasatinib, and ponatinib showed the weakened effect of growth inhibition and promoted apoptosis in cells with BCR::ABL1 compound mutations, which further verified the limitations of existing ATP-competitive TKIs targeting ABL1 for the treatment of CML patients with BCR::ABL1 compound mutations.